Disrupting the formation of LDs by a DGAT1 inhibitor (A922500) and DGAT2 inhibitor (PF‐06424439) impeded tumor growth in a xenograft mouse model of colon cancer, decreased the proportion of CD206+MHCII low immunosuppressive myeloid cells in the tumors, and enhanced the effects of anti-tumor immunity [150] (Table 2). Here, DGAT2 is linked to neoplasm.